ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. - Test2 - elhamkhani - TriplyDB

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

http://www.wikidata.org/entity/Q30580553

about

Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer Systems biology of cisplatin resistance: past, present and future Can microRNAs improve the management of lung cancer patients? A clinician's perspective 50 Years of progress in the systemic therapy of non-small cell lung cancer Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis Problems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancer FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice Lung Cancer Gene Signatures and Clinical Perspectives Prognostic value of microRNA expression in operable non-small cell lung cancer patients How individual participant data meta-analyses have influenced trial design, conduct, and analysis Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer DNA Repair Pathway Alterations in Bladder Cancer.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Adjuvant chemotherapy of non-small-cell lung cancer.Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas.Systems biology approaches to develop innovative strategies for lung cancer therapy.Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer Testing the metal of ERCC2 in predicting the response to platinum-based therapy ERCC1 and personalized medicine in lung cancer Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients.Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.The use of pharmacogenomics for selection of therapy in non-small-cell lung cancer Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma.ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.Targeting lung cancer through inhibition of checkpoint kinases.Prognostic markers in lung cancer: is it ready for prime time?Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma.

P2860

Q26863490-BC89FD0B-F6B7-4869-A6A5-13BD8F4EA093 Q26863585-ACB86367-5088-4D2C-AF29-B0914EC328AA Q26999304-E3AB2506-704B-4980-A940-15134D0679C2 Q27014978-E2DFEA32-3306-4157-811C-E9967316956F Q27853047-AD648B83-96E2-4217-9136-EFA27EF3ED96 Q28069810-2F30D4FF-5A85-47C1-9E27-ED097B48996F Q28075540-A4228F13-FC74-4FC2-BF5B-D8F0F25315B4 Q28075800-BD248B0F-DEB7-4A0C-A463-79DCAD34314B Q28387769-A8129A38-86CD-4FA6-92D8-38F8C017DE8A Q28396343-53354CB8-70D7-450C-9C9A-3FD8124AEFA0 Q28607751-49363B5E-ACE7-427B-A7A4-437B5FB8F654 Q30579903-3B73A7F0-0D77-4BAE-BA19-8CC5B87D6432 Q31038314-5110592B-166D-4925-821F-74A188E630C4 Q33577811-408BFDB8-1C8A-4381-B8CE-61D4539426D2 Q33607945-40A196B2-B4A7-463F-9F95-9D42B445C914 Q33648465-3EE25836-9485-4EBA-A72C-F721BD961604 Q33698361-74C4943E-4953-4AB2-86E3-6064E31E39CE Q33717695-7E58DE82-DA11-48E0-ACDE-98F4813EFBF6 Q33720233-2F633768-F280-4E6D-AEDB-0B6F99EF3D29 Q33914197-BFEE6937-4331-40EF-B87F-306619A03E50 Q34074425-5EB14EDB-9353-4513-B96E-C566322B3184 Q34243429-67658FC4-3794-4B2D-97CF-C5384D9699BD Q34290072-D03AD536-B9C8-43DA-9872-8A10A6D2A370 Q34357698-9E668D36-3DFD-4B5C-A0E8-9154AAFE0DBF Q34408771-82034B66-85FD-46E4-A5D4-BB47F9449A3F Q34465835-3B509E1A-CEEE-44BF-B178-537134287ECD Q34491507-5E60FF1A-4886-4E5F-A65C-DE6EF80CC822 Q34549516-894095B2-1AA7-4474-BD75-84163739D335 Q34607731-0056C5CF-0C89-47F2-9221-4880716014DC Q34623884-4E52BB7C-2A4C-404C-9609-57010D443C7D Q34657144-3B38D429-5925-4B3B-BEEE-2A0AAFD2B92B Q34775815-5223743B-433A-4037-BFA8-3713AD87AD12 Q34987379-94FCB1C8-0439-412C-B853-6C6AE8BE32EE Q35068021-B921E93F-5846-4126-A062-EB69A3182A62 Q35128547-105DC878-3DD0-41FA-ADBD-A0286E440E2D Q35200555-0651D5EC-CA3A-4563-9194-C7D22BAD566D Q35200745-8C8D4A02-7AB5-4365-9005-A6878EB958B3 Q35290441-CA00F10E-8E36-419A-AC60-11F031A22B49 Q35705620-2DF45A92-E887-468D-BA7D-4ADDD1567376 Q35813748-0989E296-062F-4CB5-836F-672DDAB5997C

P2860

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

http://www.wikidata.org/entity/Q30580553

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@ast

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@en

type

label

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@ast

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@en

prefLabel

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@ast

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@en

P1433

Q30580553-4CAA7A0D-B8D7-4F47-A3DB-A98525AD6040

P1476

Q30580553-F379A544-6746-49F3-BB0C-01DBA3173577

P2093

Q30580553-01EE3A78-EBAF-454E-8E31-E01014E4B1FC

Q30580553-16267F2D-2242-4945-90B3-6C8B7C75FD70

Q30580553-303235BD-210B-4CE0-87CB-C5CD060A7868

Q30580553-3DF77915-CF3D-46A6-9209-BB8E8FCEE7D0

Q30580553-412E377A-4C8C-43CC-80FD-35A14DBAEA6B

Q30580553-4F6635A9-4A3E-4345-A3EE-C7D38B5E1F3B

Q30580553-5E28738E-F6E0-4D3A-8EE7-852530D938BC

Q30580553-601FA2F7-25AD-4B93-B961-268C3FCD2597

Q30580553-70290367-F36A-4B6D-9F88-D4832912D6A3

Q30580553-7E411E2D-7D14-4588-93EF-B4885BA74EEF

P2860

Q30580553-0FD4B6B3-42BF-4AE2-9634-9D7FA7C28E78

Q30580553-160DCCF4-9BED-4319-AE60-9289819CF4F1

Q30580553-1B2F082F-E56D-4D3E-8213-13C5BC683017

Q30580553-24DB0172-399B-4308-8EF9-62245B4F4D99

Q30580553-277B4ED4-A193-46D1-9C7E-FDECE4A82AA4

Q30580553-2AEC2D86-C3A7-4196-99F7-072E5D7885C9

Q30580553-2EB8EAA8-DD5F-4896-AC48-D857F8FDB6AA

Q30580553-2FD0BE7D-CB99-45DC-BB99-194605D2F333

Q30580553-31C328CF-AEB6-4306-B477-392191EE6FEC

Q30580553-36F62202-FF4D-4E5F-A340-1630630EC536

P304

Q30580553-C86D0E85-280F-46F0-92F4-3BB34975433F

P31

Q30580553-F3C1C877-9987-4E93-9836-D0B75EA68C33

P356

Q30580553-10537A79-5CB9-4C06-A095-7B85555077DE

P407

Q30580553-FF881569-84DF-4EB7-BF45-32B4FD7ABF50

P433

Q30580553-9DB3394F-A402-4429-97F3-0E0D0F7DCEFE

P478

Q30580553-572A0FC7-ECEE-4B4F-92F3-86567753B193

P50

Q30580553-13BFB38C-3EA0-4B66-92F5-7F6AEE054893

Q30580553-2E42E1A9-FD77-4CA5-8BB8-1F84E193FB7F

Q30580553-A7F72EF5-B8B9-4B5B-B0EC-4E20C2DDB05C

Q30580553-B2E9321A-B40E-4DB1-8694-966ECE3E751D

Q30580553-B94E8521-FEF2-4851-8446-7E8FAEE540DD

Q30580553-CBE05308-EFEE-4733-8B22-C8C35FB7887F

Q30580553-CFCF0CE7-020F-452A-87EC-A07ECF245097

Q30580553-D247B459-CD1F-4FE9-ABA6-B080424A053F

Q30580553-DD1AB746-9B9E-4B41-8E71-3819B24FC756

P577

Q30580553-3CBA0FD3-22F0-406A-9A82-9C78562351E1

P5875

Q30580553-A047662E-1177-484A-B0D6-C3532A03D5ED

P698

Q30580553-C9E7E5CE-DF8F-4542-9BC8-6C2FDC6D58E7

P932

Q30580553-016635D1-F7FE-4F6F-913D-2D4EF4AC1020

P356

P1433

The New England Journal of Medicine

P1476

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

@en

P2093

Angélique Robin

http://www.w3.org/2001/XMLSchema#string

Annabelle Stoclin

http://www.w3.org/2001/XMLSchema#string

Ariane Dunant

http://www.w3.org/2001/XMLSchema#string

Elsa Vanhecke

http://www.w3.org/2001/XMLSchema#string

Florence Ponsonnailles

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

Frédéric Commo

http://www.w3.org/2001/XMLSchema#string

Julien Adam

http://www.w3.org/2001/XMLSchema#string

Jürgen Thomale

http://www.w3.org/2001/XMLSchema#string

Ken André Olaussen

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational analysis of the human nucleotide excision repair gene ERCC1

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.

Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

P304

1101-1110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1214271

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

368

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Charles Soria

Thierry Le Chevalier

Gwénaël Le Teuff

Ming-Sound Tsao

Jean-Pierre Pignon

Elisabeth Brambilla

Jean-Yves Douillard

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236066401

http://www.w3.org/2001/XMLSchema#string

P698

23514287

http://www.w3.org/2001/XMLSchema#string

P932

4054818

http://www.w3.org/2001/XMLSchema#string